Conference Call Participants
Jiale Song – Jefferies LLC, Research Division
Thomas Smith – Leerink Partners LLC, Research Division
Kristen Kluska – Cantor Fitzgerald & Co., Research Division
Sean Laaman – Morgan Stanley, Research Division
Tara Bancroft – TD Cowen, Research Division
Evan Seigerman – BMO Capital Markets Equity Research
Derek Archila – Wells Fargo Securities, LLC, Research Division
Douglas Tsao – H.C. Wainwright & Co, LLC, Research Division
Rami Katkhuda – LifeSci Capital, LLC, Research Division
David Nierengarten – Wedbush Securities Inc., Research Division
Martin Auster – Raymond James & Associates, Inc., Research Division
Stephen Willey – Stifel, Nicolaus & Company, Incorporated, Research Division
Danielle Brill Bongero – Truist Securities, Inc., Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Disc Medicine Corporate Call. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to your speaker today, John Quisel. Sir, please go ahead.
John Quisel
CEO, President & Director
Thank you. Good morning, and welcome, everyone. This is John Quisel speaking, CEO of Disc Medicine. And I’ll be joined today by Will Savage, our Chief Medical Officer, and Pamela Stephenson, our Chief Commercial Officer.
And we’re here to review the topline results for the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria or EPP.
Before we get started, a few preliminaries, I’d like to remind everyone that we will be making forward-looking statements, and these should be taken in context with respect to materials that we have filed with the SEC and have posted on our website.
Credit: Source link
